Assure Holdings Corp. Stock: price and insider trades · United States · SEC (Form 4)

About Assure Holdings Corp.

Assure Holdings Corp. (Nasdaq: IONM) is a U.S.-listed healthcare services company traded on the NASDAQ market in the United States. For international investors, the company is best understood as a specialized provider of intraoperative neuromonitoring, or IONM, a clinical service used during surgery to help monitor neural function in real time and reduce the risk of nerve injury. The business has historically operated as an outsourced service partner to surgeons, hospitals, and ambulatory surgery centers, with its administrative headquarters in Denver, Colorado. SEC filings show that the company’s operating footprint has evolved materially over time, and that its clinical activity was narrowed significantly in 2024. Assure’s core offering is built around two service layers. The technical component is delivered in the operating room by trained neurophysiology personnel who monitor signals throughout procedures. The professional component is provided remotely by supervising practitioners, adding redundancy, clinical oversight, and risk mitigation. In practice, this model supports surgeries where the nervous system is at risk, including neurosurgery, spine surgery, orthopedic procedures, certain cardiovascular interventions, and ENT cases. This niche is highly dependent on clinical quality, staffing depth, surgeon relationships, reimbursement dynamics, and operational reliability. The company’s modern operating structure dates back to 2016, when its Colorado subsidiary was formed, although the broader corporate history includes an older Canadian capital pool company origin that later became a Nevada corporation through domestication. Assure has been positioned as a specialized, technology-enabled healthcare services platform rather than a pure medical device company. Its competitive positioning has been based on procedural expertise and service quality, but recent filings indicate a more defensive posture as the company has worked through portfolio reshaping and strategic review. A major recent development came in 2024, when Assure sold most of its clinical operations, equipment, and contracts. After that transaction, the company stated that it continued to provide IONM services only in limited markets, primarily Arizona and Montana. Assure also entered into a merger agreement with Danam Health in February 2024, but terminated that agreement in June 2024. Those events suggest that the business has been in transition, with management exploring strategic alternatives while trying to preserve value. From an equity-analysis perspective, Assure should be viewed as a micro-cap healthcare situation with elevated execution and liquidity risk, rather than a stable operating franchise. The company remains relevant to investors following SEC Form 4 insider transactions, but the more important investment narrative today is restructuring, asset rationalization, and strategic optionality. In short, Assure is a small U.S. NASDAQ-listed healthcare services company whose recent history is defined less by expansion than by contraction and repositioning. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1798270/000179827024000012/ionm-20231231x10k.htm?utm_source=openai))